EMMAOTCPharmaceutical PreparationsFiscal year ends December 31
Emmaus Life Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.05−0.01 (-14.38%)
Close on Oct 19, 2026
- Market cap
- $6.03M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.0381 (+320.2%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Emmaus Life Sciences, Inc. reported revenue of $15.53M for the twelve months to Jun 30, 2026. Free cash flow was -$12.00K.
Revenue
$15.53M
TTM Q2 2026
Operating income
$4.55M
TTM Q2 2026
Free cash flow
-$12.00K
FY2025
EPS, diluted
-$0.09
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $6.03M
- P/E ratio
- –
- Price to sales
- 0.39
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -0.20%
Fundamentals
- Revenue
- $15.53M
- Net income
- -$6.02M
- EPS, diluted
- -$0.09
- Free cash flow
- -$12.00K
- Book value per share
- -$0.55
- Diluted shares
- 121M
Fifteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
$15.53M
Gross profit
$14.54M
Operating income
$4.55M
Net income
-$6.02M
EPS, diluted
-$0.09
Free cash flow
–
Reported periodTrailing twelve months